Plaintiffs defend US antitrust claims against Takeda, Twi over Dexilant
MLex Summary: Direct purchasers and retailers of Dexilant opposed a motion to dismiss US antitrust claims against Takeda Pharmaceutical and Twi Pharmaceuticals, arguing that their claims are timely under the continuing violation...To view the full article, register now.
Already a subscriber? Click here to view full article